Diffuse Panbronchiolitis

Clinics in Chest Medicine

Volumn 33, Issue 2, 2012, Pages 297-305

  Kudoh, Shoji ^a,b   Keicho, Naoto ^c  

^a Japan Anti Tuberculosis Association   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Asian disease; Chronic airway infection; Diffuse panbronchiolitis; Macrolide antibiotics

Indexed keywords

AZITHROMYCIN; CHEMOTACTIC FACTOR; CLARITHROMYCIN; ERYTHROMYCIN; HLA ANTIGEN; HLA B54 ANTIGEN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; UNCLASSIFIED DRUG;

BACTERIAL VIRULENCE; BIOACCUMULATION; BRONCHIOLITIS; CELL METABOLISM; CELLULAR DISTRIBUTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DIAGNOSTIC VALUE; DIFFUSE PANBRONCHIOLITIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HAEMOPHILUS INFLUENZAE; HUMAN; HYPERSALIVATION; IMAGE ANALYSIS; IMAGE DISPLAY; LOW DRUG DOSE; LUNG FUNCTION TEST; MEDICAL HISTORY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; REVIEW; SURVIVAL RATE; SYNDROME DELINEATION; THORAX RADIOGRAPHY; UPREGULATION;

ANTI-BACTERIAL AGENTS; BRONCHIOLITIS; FAR EAST; HAEMOPHILUS INFECTIONS; HUMANS; MACROLIDES; PRACTICE GUIDELINES AS TOPIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84861563480     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2012.02.005     Document Type: Review

References (60)

1. Yamanaka A., Saiki S., Tamura S., et al. Naika 1969, 23(3):442-451. [in Japanese].
2. Homma H., Yamanaka A., Tanimoto S., et al. Diffuse panbronchiolitis. A disease of the transitional zone of the lung. Chest 1983, 83(1):63-69.
3. Homma H. Diffuse panbronchiolitis. Jpn J Med 1986, 25(3):329-334.
4. Kudoh S., Uetake T., Hagiwara K., et al. Nihon Kyobu Shikkan Gakkai Zasshi 1987, 25(6):632-4215. [in Japanese].
5. Odaka M., Saito N., Hosoda Y., et al. [An epidemiological study of DPB in a large company. Annual report on the study of interstitial lung disease in 1980] 1981, Ministry of Health and Welfare of Japan, Tokyo, p. 25-8 [in Japanese].
6. Kim Y.W., Han S.K., Shim Y.S., et al. The first report of diffuse panbronchiolitis in Korea: five case reports. Intern Med 1992, 31(5):695-701.
7. Tsang K.W., Ooi C.G., Ip M.S., et al. Clinical profiles of Chinese patients with diffuse panbronchiolitis. Thorax 1998, 53(4):274-280.
8. Fitzgerald J.E., King T.E., Lynch D.A., et al. Diffuse panbronchiolitis in the United States. Am J Respir Crit Care Med 1996, 154(2 Pt 1):497-503.
9. Brugiere O., Milleron B., Antoine M., et al. Diffuse panbronchiolitis in an Asian immigrant. Thorax 1996, 51(10):1065-1067.
10. Sugiyama Y., Kudoh S., Maeda H., et al. Analysis of HLA antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1990, 141(6):1459-1462.
11. Keicho N., Tokunaga K., Nakata K., et al. Contribution of HLA genes to genetic predisposition in diffuse panbronchiolitis. Am J Respir Crit Care Med 1998, 158(3):846-850.
12. Park M.H., Kim Y.W., Yoon H.I., et al. Association of HLA class I antigens with diffuse panbronchiolitis in Korean patients. Am J Respir Crit Care Med 1999, 159(2):526-529.
13. Keicho N., Ohashi J., Tamiya G., et al. Fine localization of a major disease-susceptibility locus for diffuse panbronchiolitis. Am J Hum Genet 2000, 66(2):501-507.
14. Hijikata M., Matsushita I., Tanaka G., et al. Molecular cloning of two novel mucin-like genes in the disease-susceptibility locus for diffuse panbronchiolitis. Hum Genet 2011, 129(2):117-128.
15. Maeda M., Saiki S., Yamanaka A. Serial section analysis of the lesions in diffuse panbronchiolitis. Acta Pathol Jpn 1987, 37(5):693-704.
16. Sato A., Chida K., Iwata M., et al. Study of bronchus-associated lymphoid tissue in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1992, 146(2):473-478.
17. Todate A., Chida K., Suda T., et al. Increased numbers of dendritic cells in the bronchiolar tissues of diffuse panbronchiolitis. Am J Respir Crit Care Med 2000, 162(1):148-153.
18. Mukae H., Kadota J., Kohno S., et al. Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis. Am J Respir Crit Care Med 1995, 152(2):613-618.
19. Kawakami K., Kadota J., Iida K., et al. Phenotypic characterization of T cells in bronchoalveolar lavage fluid (BALF) and peripheral blood of patients with diffuse panbronchiolitis; the importance of cytotoxic T cells. Clin Exp Immunol 1997, 107(2):410-416.
20. Ichikawa Y., Koga H., Tanaka M., et al. Neutrophilia in bronchoalveolar lavage fluid of diffuse panbronchiolitis. Chest 1990, 98(4):917-923.
21. Ichikawa Y., Ninomiya H., Koga H., et al. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis 1992, 146(1):196-203.
22. Kadota J., Sakito O., Kohno S., et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993, 147(1):153-159.
23. Kusano S., Kadota J., Kohno S., et al. Effect of roxithromycin on peripheral neutrophil adhesion molecules in patients with chronic lower respiratory tract disease. Respiration 1995, 62(4):217-222.
24. Mukae H., Kadota J., Ashitani J., et al. Elevated levels of soluble adhesion molecules in serum of patients with diffuse panbronchiolitis. Chest 1997, 112(6):1615-1621.
25. Akira M., Kitatani F., Lee Y.S., et al. Diffuse panbronchiolitis: evaluation with high-resolution CT. Radiology 1988, 168(2):433-438.
26. Nishimura K., Kitaichi M., Izumi T., et al. Diffuse panbronchiolitis: correlation of high-resolution CT and pathologic findings. Radiology 1992, 184(3):779-785.
27. Koyama H., Nishimura K., Mio T., et al. Bronchial responsiveness and acute bronchodilator response in chronic obstructive pulmonary disease and diffuse panbronchiolitis. Thorax 1994, 49(6):540-544.
28. Takizawa H., Tadokoro K., Miyoshi Y., et al. Nihon Kyobu Shikkan Gakkai Zasshi 1986, 24(3):257-263. [in Japanese].
29. Nakata K. Revision of clinical guidelines for DPB. Annual report on the study of diffuse lung disease in 1998 1999, Ministry of Health and Welfare of Japan, Tokyo, p. 109-111 [in Japanese].
30. Yamamoto M. A double-blind placebo-controlled study on the therapeutic effect of erythromycin on DPB. Annual report on the study of diffuse lung disease in 1990 1991, Ministry of Health and Welfare of Japan, Tokyo, p. 18-20 [in Japanese].
31. Kudoh S., Azuma A., Yamamoto M., et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998, 157(6 Pt 1):1829-1832.
32. Tamaoki J., Takeyama K., Tagaya E., et al. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrobial Agents Chemother 1995, 39(8):1688-1690.
33. Nakamura H., Fujishima S., Inoue T., et al. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J 1999, 13(6):1371-1379.
34. Kobayashi H., Takeda H., Sakayori S., et al. Kansenshogaku Zasshi 1995, 69(6):711-722. [in Japanese].
35. Oritsu M. Ther Res 1990, 11:545-546. [in Japanese].
36. Nakata K., Taguchi Y., Kudoh S. Therapeutic guidelines for DPB. Annual Report on the study of diffuse lung disease in 1999 2000, Ministry of Health and Welfare of Japan, Tokyo, p. 111 [in Japanese].
37. Yamamoto M., Kondo A., Tamura M., et al. Nihon Kyobu Shikkan Gakkai Zasshi 1990, 28(10):1305-1313. [in Japanese].
38. Crosbie P.A., Woodhead M.A. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009, 33:171-181. [review].
39. Friedlander A.L., Albert R.K. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010, 138:1202-1212. [review].
40. Altenburg J., de Graaff C.S., van der Werf T.S., et al. Immunomodulatory effects of macrolide antibiotics-part1: biological mechanisms. Respiration 2011, 81(1):67-74. [review].
41. Altenburg J., de Graaff C.S., van der Werf T.S., et al. Immunomodulatory effects of macrolide antibiotics-part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration 2011, 81(1):75-87. [review].
42. Goswami S.K., Kivity S., Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis 1990, 141(1):72-78.
43. Tamaoki J., Isono K., Sakai N., et al. Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. Eur Respir J 1992, 5(2):234-238.
44. Oishi K., Sonoda F., Kobayashi S., et al. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun 1994, 62(10):4145-4152.
45. Sakito O., Kadota J., Kohno S., et al. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996, 63(1):42-48.
46. Takizawa H., Desaki M., Ohtoshi T., et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997, 156(1):266-271.
47. Desaki M., Takizawa H., Ohtoshi T., et al. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000, 267(1):124-128.
48. Keicho N., Kudoh S., Yotsumoto H., et al. Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. J Antibiot (Tokyo) 1993, 46(9):1406-1413.
49. Morikawa K., Oseko F., Morikawa S., et al. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. Antimicrobial Agents Chemother 1994, 38(11):2643-2647.
50. Keicho N., Kudoh S., Yotsumoto H., et al. Erythromycin promotes monocyte to macrophage differentiation. J Antibiot (Tokyo) 1994, 47(1):80-89.
51. Kita E., Sawaki M., Oku D., et al. Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin. J Antimicrob Chemother 1991, 27(3):273-284.
52. Sakata K., Yajima H., Tanaka K., et al. Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro. Am Rev Respir Dis 1993, 148(4 Pt 1):1061-1065.
53. Davies D.G., Parsek M.R., Pearson J.P., et al. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998, 280(5361):295-298.
54. Tateda K., Comte R., Pechere J.C., et al. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrobial Agents Chemother 2001, 45(6):1930-1933.
55. Jaffe A., Francis J., Rosenthal M., et al. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998, 351(9100):420.
56. Suzuki T., Yanai M., Yamaya M., et al. Erythromycin and common cold in COPD. Chest 2001, 120(3):730-733.
57. Seemungal T.A., Wilkinson T.M., Hurst J.R., et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008, 178:1139-1147.
58. Albert R.K., Connett J., Bailey W.C. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011, 365:689-698.
59. Yamaya M., Shinya K., Hatachi Y., et al. Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells. J Pharmacol Exp Ther 2010, 333(1):81-90.
60. Bermejo-Martin J.F., Kelvin D.J., Eiros J.M., et al. Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains. J Infect Dev Ctries 2009, 3(3):159-161.